

References

I-201

1. Yukio A, Coelho T, Berk J, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8(31):1-18.
2. Adams D, Gonzalez-Duarte A, O'Riordan W, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:11-21.
3. Adams D, Suhr O, Dyck P, et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. *BMC Neuro*. 2017;17:1-12.
4. Gonzalez-Duarte A, Lem-Carrillo M, & Cardenas-Soto K. Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy. *Amyloid*. 2013;20(4):221-225.
5. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT:CMT-0009(SR).
6. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
7. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
8. Solomon SD, Adams D, Kristen A et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. *Circulation*. 2019;139:431-443.
9. Coelho T, Adams D, Conceicao I, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. *Orphanet J Rare Dis*. 2020;15(1):179.
10. Adams D, Tournev I, Taylor M et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. *Amyloid*. 2023;30(1):1-9.
11. Patisiran In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 25, 2022.
12. Vutrisiran In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 16, 2023.
13. Clinical Pharmacology™ Compendium. 2025.Tampa FL: Gold Standard, Inc. Patisiran.
14. Clinical Pharmacology™ Compendium. 2025.Tampa FL: Gold Standard, Inc. Vutrisiran.
15. Micromedex DrugDex Compendium®. 2025.Patisiran.
16. Micromedex DrugDex Compendium®. 2025.Vutrisiran.
17. Onpattro® (patisiran) lipid complex injection, for intravenous use [prescribing information] Alnylam Pharmaceuticals, Inc., Cambridge, MA. Revised 01/2023.
18. Amvuttra™ (vutrisiran) injection, for subcutaneous use [prescribing information] Alnylam Pharmaceuticals, Inc., Cambridge, MA. Revised 03/2025.
19. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A

Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023;81(11):1076-1126.

20. American Society of Nuclear Cardiology. Diagnose, Differentiate, and Manage Cardiac Amyloidosis. Available at: <https://www.asnc.org/cardiacamyloidosis>. 2025. Accessed April 2, 2025.
21. Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. *Heart Fail Rev*. 2024 Oct 1;30(1):69–73.
22. Ioannou A, Fontana M, Gillmore J. RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis. *BioDrugs*. 2023 Feb 16;37(2):127–142.